Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)

DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma.

DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024.

The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well.

Biotech Investing: How PRVs Can Unlock Major Opportunities

Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%.

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

Although US stocks closed higher on Monday, there were a few notable insider trades.

The Nasdaq held near 52-week highs while small caps ramped up.

The clinical-stage biotech released early trial news regarding its lead therapy candidate.

ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference.

Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!'

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.